"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 5 | 7 |
| 2002 | 5 | 6 | 11 |
| 2003 | 5 | 5 | 10 |
| 2004 | 4 | 4 | 8 |
| 2005 | 6 | 2 | 8 |
| 2006 | 2 | 2 | 4 |
| 2007 | 4 | 3 | 7 |
| 2008 | 3 | 7 | 10 |
| 2009 | 12 | 5 | 17 |
| 2010 | 8 | 6 | 14 |
| 2011 | 8 | 6 | 14 |
| 2012 | 3 | 9 | 12 |
| 2013 | 8 | 7 | 15 |
| 2014 | 17 | 10 | 27 |
| 2015 | 6 | 5 | 11 |
| 2016 | 14 | 5 | 19 |
| 2017 | 17 | 10 | 27 |
| 2018 | 14 | 13 | 27 |
| 2019 | 14 | 14 | 28 |
| 2020 | 22 | 16 | 38 |
| 2021 | 13 | 21 | 34 |
| 2022 | 3 | 22 | 25 |
| 2023 | 2 | 18 | 20 |
| 2024 | 10 | 13 | 23 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025 Mar 11; 9(5):1013-1023.
-
Immunotherapy-related neurotoxicity in the central nervous system of children with cancer. Neuro Oncol. 2025 Mar 07; 27(3):625-643.
-
Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma. J Immunother Cancer. 2025 Feb 12; 13(2).
-
Application and Expectations for Immune Checkpoint Blockade of LAG3 and TIGIT. Annu Rev Med. 2025 Jan; 76(1):189-205.
-
Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Cancer Discov. 2025 Jan 13; 15(1):162-178.
-
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy? Neuro Oncol. 2025 Jan 12; 27(1):33-49.
-
OSBPL3 modulates the immunosuppressive microenvironment and predicts therapeutic outcomes in pancreatic cancer. Biol Direct. 2025 Jan 09; 20(1):5.
-
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing. J Immunother Cancer. 2025 Jan 08; 13(1).
-
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2025 Jan 07; 39(1-2):36-63.
-
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025 Mar; 39(3):555-567.